Nindanib 100mg Capsule

About

Nindanib 100mg Capsule contains Nintedanib, a potent oral tyrosine kinase inhibitor that targets multiple growth factor receptors crucial for cell proliferation, angiogenesis, and fibrosis. Specifically, it inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR). By blocking these key signaling pathways, Nintedanib effectively reduces the formation of new blood vessels that feed tumors and slows down the excessive deposition of fibrous tissue in organs. This dual anti-angiogenic and anti-fibrotic action makes it a valuable treatment for progressive fibrotic lung diseases, such as idiopathic pulmonary fibrosis, and certain types of cancer, by mitigating disease progression and improving patient outcomes through its targeted molecular mechanism.

Uses

• Treatment of idiopathic pulmonary fibrosis (IPF).
• Treatment of other chronic fibrosing interstitial lung diseases with a progressive phenotype.
• Treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD).
• In combination with docetaxel for advanced non-small cell lung cancer (NSCLC) of adenocarcinoma histology.

Directions For Use

Take Nindanib 100mg Capsule orally, usually twice daily, approximately 12 hours apart, with food. Swallow the capsule whole with water; do not chew or crush.

Benefits

• Slows the progression of idiopathic pulmonary fibrosis.
• Reduces the rate of decline in lung function.
• Effective in various chronic fibrosing interstitial lung diseases.
• Offers a targeted therapy option for specific lung cancers.
• Improves quality of life for patients with fibrotic lung conditions.
• Oral administration for patient convenience.

Side Effects

• Diarrhea
• Nausea
• Vomiting
• Abdominal pain
• Decreased appetite
• Weight loss
• Liver enzyme elevation
• Hypertension
• Headache
• Bleeding events
• Arterial thromboembolic events
• Gastrointestinal perforation

Safety Measures

• Alcohol - Avoid excessive alcohol consumption, as it may increase the risk of liver enzyme elevation, a known side effect of Nindanib.
• Pregnancy - Nindanib is embryotoxic and teratogenic. Women of childbearing potential must use highly effective contraception during treatment and for at least 3 months after the last dose.
• Breastfeeding - It is unknown if Nindanib is excreted in human milk. Due to the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment.
• Liver - Nindanib is primarily metabolized by the liver. Patients with hepatic impairment require dose adjustments or may not be suitable for treatment. Liver function should be monitored regularly.
• Kidney - No dose adjustment is required for mild to moderate renal impairment. Use with caution in severe renal impairment due to limited data.
• Lung - While used for lung conditions, monitor for worsening respiratory symptoms or new onset of interstitial lung disease, though rare.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.